Search

Your search keyword '"Monika Joshi"' showing total 245 results

Search Constraints

Start Over You searched for: Author "Monika Joshi" Remove constraint Author: "Monika Joshi"
245 results on '"Monika Joshi"'

Search Results

1. Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib/II study BTCRC-GU16-043

3. Assessment of Ameliorative Effect of Myrica esculenta in a DSS-Induced Murine Model against Ulcerative Colitis

4. Management of Fibroblast Growth Factor Inhibitor Treatment–emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

5. Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study

6. FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation

7. Environmental-friendly algal-mediated magnetic activated carbon for adsorptive removal of contaminants from water

8. Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer ConsortiumResearch in context

9. Computerized Decision Support for Bladder Cancer Treatment Response Assessment in CT Urography: Effect on Diagnostic Accuracy in Multi-Institution Multi-Specialty Study

10. Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023

11. Equimolar ZnO-CdS nanocomposite for enhanced photocatalytic performance

12. Nanotechnology-based strategies for effective delivery of phytoconstituents for the management of rheumatoid arthritis

13. Comparative effectiveness of surgery versus external beam radiation with/without brachytherapy in high‐risk localized prostate cancer

14. Polycystic ovarian syndrome: A review covering phytoconstituents for its outstrip management

15. Author Correction: FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation

16. Structural Paradigms in the Recognition of the Nucleosome Core Particle by Histone Lysine Methyltransferases

17. Combinational approach using solid dispersion and semi-solid matrix technology to enhance in vitro dissolution of telmisartan

18. Sputtered SnO2/ZnO Heterostructures for Improved NO2 Gas Sensing Properties

19. nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC

20. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.

22. Effect of computerized decision support on diagnostic accuracy and intra-observer variability in multi-institutional observer performance study for bladder cancer treatment response assessment in CT urography.

24. Disparities in Access to Novel Systemic Therapies in Patients With Urinary Tract Cancer: Propagating Access, Policies and Resources Uniformly

25. Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19

27. A comparison of end-of-life care patterns between older patients with both cancer and Alzheimer's disease and related dementias versus those with only cancer

28. Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma

32. Data from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19

33. Supplementary Figure from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19

37. Angelica gigas: Signature Compounds, In Vivo Anticancer, Analgesic, Neuroprotective and Other Activities, and the Clinical Translation Challenges

38. Development of a multifunctional toolkit of intrabody-based biosensors recognizing the V5 peptide tag: highlighting applications with G protein-coupled receptors

40. Multidisciplinary Management and Radiotherapy Recommendations for Clinically and Pathologically Node-positive Bladder Cancer

42. Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer

43. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

44. Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma

45. ​Assessment of the Levels of Biomarkers of Oxidative Stress during Peri-parturient Period in Gir Cows

46. Effect of Herbal Feed Additives Fenugreek (Trigonella foenum-graecum) Seed Powder and Onion (Allium cepa) Powder on Haemato-biochemical and Carcass Characteristics of Broilers

47. Effect of Addition of Turmeric (Curcuma longa) and Ginger (Zingiber officinale) on Feed Intake and Growth Performance in Broilers

49. Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes

Catalog

Books, media, physical & digital resources